- Copycats for complex medicines like EpiPen to be top priority
Scott Gottlieb has long advocated revamping approval process
President Donald Trump’s pick to head the U.S. Food and Drug Administration is among the most vigorous advocates of lowering drug costs by approving cheap generics faster, an initiative aimed directly at the profit centers of major companies.
Scott Gottlieb, a former FDA deputy commissioner, would make streamlining approvals his top priority, according to a person familiar with the administration’s thinking. He’s particularly focused on complex medications that combine old drugs with newer delivery devices, as well as those with unusually complicated formulations.
Read Full Article Here >>